We are delighted to share news of IGA Professor David Garway-Heath’s recent international and national awards from the American Glaucoma Society (AGS) and the UK Advisory Committee on Clinical Excellence Awards (ACCEA).
The AGS will present Professor David (Ted) Garway-Heath with the prestigious International Scholar Award in February 2020. Ted, who is Professor of Ophthalmology at the UCL Institute of Ophthalmology (IoO) and Consultant at Moorfields Eye Hospital alongside being IGA Professor, receives the award in recognition of his “lifetime contributions to glaucoma research, education, and patient care”.
In the UK, Prof. Garway-Heath has been awarded a Gold Clinical Excellence Award in recognition of his contributions to the NHS after intense scrutiny by the Advisory Committee on Clinical Excellence Awards (ACCEA), which is sponsored by the Department and Health and Social Care. The award is a public acknowledgement of his professional expertise and sustained and dedicated contribution to the NHS over and above contractual requirements.
About Professor Garway-Heath
In addition to his clinical work, Prof. Garway-Heath leads research in visual assessment and imaging at the NIHR Biomedical Research Centre at Moorfields and UCL IoO. He also conducts his own research aimed at improving care outcome by developing and evaluating diagnostics, improving clinical trial design to reduce the time taken to establish treatment benefits, identifying risk factors for disease progression, and developing decision-support software to provide evidence-based guidance in clinical care.
Prof. Garway-Heath’s 2015 Lancet paper reporting the findings of his landmark UK Glaucoma Treatment Study is highly cited worldwide and has been referenced in the NICE Glaucoma Guidelines for the diagnosis and treatment of glaucoma. The map he developed to relate structure and function in glaucoma has now been incorporated into diagnostic devices used in the clinic worldwide.
Prof. Garway-Heath has been consecutively cited in The Ophthalmologist magazine’s power list as one of the 100 most influential people in ophthalmology worldwide, and last year he was voted ‘top mentor worldwide’ on the power list for his work mentoring younger colleagues and helping them develop leadership skills. He has also been driving a mentorship programme for the European Glaucoma Society (EGS), of which he is President, called Next Generation Partnership (NGP). Since its launch in 2017, the NGP programme has enrolled around 100 glaucoma specialists across all European countries.
He has also undertaken a European-wide patient support initiative. Currently, patient support organisations are not as well developed in some countries as in the UK, which means that patients often cannot access support outside the clinical environment. The first step of this initiative has been accomplished by allowing all EGS members to gain direct access to information on patient education and support provided by the IGA. The IGA was selected as it is one of the best-established patient organisations in Europe. A further step of the initiative was launched at the 2018 EGS biennial congress to promote the establishment of a Europe-wide Patient Support Organisation Network with the support from the IGA.
This year’s EGS congress in Brussels will celebrate the Society’s 40th anniversary and will be marked by the launch of an initiative dedicated to patient input into care provision and research priorities. The IGA will be taking an active part in this initiative.
Find out more
– View Professor Garway-Heath’s academic profile https://www.ucl.ac.uk/ioo/research/academics/garway-heath
– Visit the EGS website https://www.eugs.org/eng/default.asp
– Visit the AGS website https://www.americanglaucomasociety.net/home
– Read about the NHS Clinical Excellence Awards https://www.gov.uk/government/organisations/advisory-committee-on-clinical-excellence-awards
We will be changing our name to Glaucoma UK in summer 2020.
What’s in a name? Well, as it turns out, a lot. The decision to change our name follows lengthy discussions with patients and professionals about how we can reach more people affected by glaucoma in the UK. When we reviewed the evidence, we found that our current name is holding us back: many people don’t realise we are a charity, and many don’t think we offer support services to people in the UK....Read More